Skip to Content
Morningstar

Merck KGaA Earnings: Weak Life Science and Electronics Segments Cut Into 2023 Outlook

""
Securities In This Article
Merck KGaA
(MRK)

Narrow-moat Merck KGaA MRK delivered weak second-quarter results, and with these trends, management reduced its 2023 outlook. Mild tinkering with our near-term expectations does not materially affect our fair value estimates for the firm (EUR 171/$38), though, and shares continue to trade near fair value, in our opinion.

In the quarter, Merck turned in weak results, reflecting the ongoing reset in life sciences and decline in electronics. On an organic basis, sales declined 1% while adjusted EBITDA declined 7%. The life sciences segment faced significant growth hurdles from a tough comparable period of COVID-19-related demand while inventory destocking took its toll on the process solutions business, in particular. Merck’s electronics segment reflected industrywide declines in semiconductor solutions while display and surface solutions also dropped. Offsetting those weak segments, Merck’s healthcare segment remained robust by turning in low-double-digit organic growth, driven primarily by new products Bavencio (oncology) and Mavenclad (multiple sclerosis), while legacy product Erbitux (oncology) grew on expansion in China and legacy product Rebif (multiple sclerosis) faced ongoing competitive pressure.

Considering the weak overall trends, the company has reduced its overall expectations based on challenges in the life science and electronics segments. Now for 2023, the company expects organic sales in a range of a 2% decline to a 2% increase (down from a low-single-digit increase previously) and adjusted EBITDA to decline 3% to 9% (down from a low-single digit decline previously.) Positively, management maintained its 2025 goal for EUR 25 billion of sales, and making mild adjustments to our near-term forecast does not materially change our fair value estimate for Merck.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

More in Stocks

About the Author

Julie Utterback

Senior Equity Analyst
More from Author

Julie Utterback is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. Within the healthcare industry, she covers medical technology and service companies. She is also the chairperson of the equity research team’s capital allocation methodology.

Utterback joined Morningstar in 2005 as an equity analyst in the healthcare industry. At that time, she covered medical technology companies, including orthopedic device, medical equipment, and cardiac device firms. In 2010, she joined Morningstar's credit research team, initiating coverage of the entire healthcare industry and generally helping the organization expand and maintain its credit coverage across many industries. She held that senior credit analyst role until April 2019, when she returned to the equity team to cover medical technology and service companies.

Prior to joining Morningstar, Utterback was an equity analyst at State Farm Insurance for several years. She holds a bachelor's degree in finance from the University of Illinois Urbana-Champaign. She also holds the Chartered Financial Analyst® designation.

Sponsor Center